MX2023000806A - Métodos para encapsular polinucleótidos en tamaños reducidos de nanopartículas lipídicas y formulación novedosa de estos. - Google Patents
Métodos para encapsular polinucleótidos en tamaños reducidos de nanopartículas lipídicas y formulación novedosa de estos.Info
- Publication number
- MX2023000806A MX2023000806A MX2023000806A MX2023000806A MX2023000806A MX 2023000806 A MX2023000806 A MX 2023000806A MX 2023000806 A MX2023000806 A MX 2023000806A MX 2023000806 A MX2023000806 A MX 2023000806A MX 2023000806 A MX2023000806 A MX 2023000806A
- Authority
- MX
- Mexico
- Prior art keywords
- lipid
- methods
- polinucleotides
- encapsulating
- lipid nanoparticles
- Prior art date
Links
- 150000002632 lipids Chemical class 0.000 title abstract 7
- 238000009472 formulation Methods 0.000 title abstract 4
- 239000000203 mixture Substances 0.000 title abstract 4
- 238000000034 method Methods 0.000 title abstract 2
- 239000002105 nanoparticle Substances 0.000 title abstract 2
- 108020005202 Viral DNA Proteins 0.000 abstract 1
- 210000000056 organ Anatomy 0.000 abstract 1
- 239000002245 particle Substances 0.000 abstract 1
- 239000013598 vector Substances 0.000 abstract 1
- 239000013603 viral vector Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/5123—Organic compounds, e.g. fats, sugars
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
- A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
- A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
- A61K48/0033—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being non-polymeric
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Organic Chemistry (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- General Chemical & Material Sciences (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Dispersion Chemistry (AREA)
- Optics & Photonics (AREA)
- Nanotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063053274P | 2020-07-17 | 2020-07-17 | |
| US202163194620P | 2021-05-28 | 2021-05-28 | |
| PCT/US2021/042033 WO2022016089A2 (en) | 2020-07-17 | 2021-07-16 | Methods for encapsulating polynucleotides into reduced sizes of lipid nanoparticles and novel formulation thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023000806A true MX2023000806A (es) | 2023-04-11 |
Family
ID=79555025
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023000806A MX2023000806A (es) | 2020-07-17 | 2021-07-16 | Métodos para encapsular polinucleótidos en tamaños reducidos de nanopartículas lipídicas y formulación novedosa de estos. |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20230320993A1 (https=) |
| EP (1) | EP4181948A4 (https=) |
| JP (1) | JP2023534043A (https=) |
| KR (1) | KR20230052895A (https=) |
| CN (1) | CN116437964A (https=) |
| AU (1) | AU2021307952A1 (https=) |
| CA (1) | CA3186033A1 (https=) |
| IL (1) | IL299896A (https=) |
| MX (1) | MX2023000806A (https=) |
| WO (1) | WO2022016089A2 (https=) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11752213B2 (en) | 2015-12-21 | 2023-09-12 | Duke University | Surfaces having reduced non-specific binding and antigenicity |
| EP3515928B1 (en) | 2016-09-23 | 2026-01-28 | Duke University | Unstructured non-repetitive polypeptides having lcst behavior |
| WO2019006374A1 (en) | 2017-06-30 | 2019-01-03 | Duke University | ORDER AND DISORDER AS A DESIGN PRINCIPLE FOR STIMULI-SENSITIVE BIOPOLYMER NETWORKS |
| US12296018B2 (en) | 2018-01-26 | 2025-05-13 | Duke University | Albumin binding peptide-drug (AlBiPeD) conjugates and methods of making and using same |
| EP3788343B1 (en) | 2018-04-30 | 2024-03-27 | Duke University | Stimuli-responsive peg-like polymer-based drug delivery platform |
| WO2020051541A1 (en) | 2018-09-07 | 2020-03-12 | Duke University | Nanoparticulate drug delivery systems |
| CN113166783B (zh) | 2018-10-09 | 2024-10-11 | 不列颠哥伦比亚大学 | 包含无有机溶剂和去污剂的转染活性囊泡的组合物和系统以及与之相关的方法 |
| US11512314B2 (en) | 2019-07-12 | 2022-11-29 | Duke University | Amphiphilic polynucleotides |
| IL296763B2 (en) | 2020-03-27 | 2026-04-01 | Generation Bio Co | New lipids and their nanoparticle compositions |
| KR20230172570A (ko) | 2021-04-20 | 2023-12-22 | 제너레이션 바이오 컴퍼니 | 양이온성 지질 및 이의 조성물 |
| US12508225B2 (en) | 2021-05-28 | 2025-12-30 | Beijing Tricisionbio Therapeutics Inc. | Lipid compound and use thereof in delivery of nucleic acid |
| WO2022266032A1 (en) * | 2021-06-14 | 2022-12-22 | Generation Bio Co. | Cationic lipids and compositions thereof |
| US20250281596A1 (en) * | 2021-09-28 | 2025-09-11 | Seqirus Inc. | Ionizable cationic compound |
| CN118201605A (zh) * | 2021-10-25 | 2024-06-14 | 杜克大学 | 基于poegma的脂质纳米粒子 |
| WO2023190166A1 (ja) * | 2022-03-28 | 2023-10-05 | 日油株式会社 | ジスルフィド結合を有するカチオン性脂質、これを含む脂質膜構造体、これらのいずれかを含む核酸導入剤及び医薬品組成物、核酸を細胞又は標的細胞内へ導入する方法、及び細胞医薬品の製造方法 |
| CN114685784B (zh) * | 2022-04-26 | 2023-09-15 | 北京清科胜因生物科技有限公司 | 一种用于核酸递送的聚(2-噁唑啉)脂质与脂质纳米颗粒及应用 |
| EP4536197A1 (en) * | 2022-06-07 | 2025-04-16 | Generation Bio Co. | Lipid nanoparticle compositions and uses thereof |
| CN115105584B (zh) * | 2022-06-28 | 2023-03-31 | 长春生物制品研究所有限责任公司 | 一种卡式瓶多剂量笔式注射组合包装的干扰素注射液 |
| WO2024037577A1 (en) * | 2022-08-18 | 2024-02-22 | Suzhou Abogen Biosciences Co., Ltd. | Composition of lipid nanoparticles |
| EP4594299A1 (en) * | 2022-09-27 | 2025-08-06 | Reinvigoron TheraTech, Inc. | Compounds with cleavable disulfide moieties |
| CN120091992A (zh) * | 2022-11-08 | 2025-06-03 | 三养控股公司 | 阳离子脂质及其制备方法 |
| WO2024119103A1 (en) | 2022-12-01 | 2024-06-06 | Generation Bio Co. | Lipid nanoparticles comprising nucleic acids and lipid-anchored polymers |
| EP4704855A1 (en) * | 2023-04-26 | 2026-03-11 | Saliogen Therapeutics, Inc. | Lipid nanoparticle (lnp) formulations |
| US12311033B2 (en) | 2023-05-31 | 2025-05-27 | Capstan Therapeutics, Inc. | Lipid nanoparticle formulations and compositions |
| WO2025043146A2 (en) * | 2023-08-24 | 2025-02-27 | Molecular Axiom Inc. | Lipid nanoparticle compositions and methods of using same |
| WO2025064850A1 (en) | 2023-09-22 | 2025-03-27 | BioNTech SE | Rna constructs with n-terminal degrons to enhance an immune response |
| WO2025106754A1 (en) | 2023-11-15 | 2025-05-22 | BioNTech SE | Coronavirus vaccine |
| GB202416789D0 (en) | 2023-11-15 | 2025-01-01 | BioNTech SE | SARS-COV-2 immunogenic compositions |
| WO2025149492A1 (en) | 2024-01-08 | 2025-07-17 | BioNTech SE | Rna encoding an immune inhibitory il-1 family member |
| WO2025166238A1 (en) * | 2024-01-31 | 2025-08-07 | Orna Therapeutics, Inc. | Fast-shedding polyethylene glycol lipids |
| WO2025178465A1 (ko) * | 2024-02-19 | 2025-08-28 | 주식회사 메디치바이오 | 신규한 이온화 지질 및 이를 이용한 지질 나노입자 조성물 |
| WO2025230906A1 (en) * | 2024-04-29 | 2025-11-06 | Saliogen Therapeutics, Inc. | Lipid nanoparticle (lnp) formulations |
| WO2025237830A1 (en) * | 2024-05-15 | 2025-11-20 | Evonik Operations Gmbh | Polyoxyalkylene-1,2-di(alkyloxy)propanoxy-carbonylaminopropyl compounds, wherein the polyoxyalkylene is a poly(ethylene oxide) having c1 to c3-alkyloxymethyl side chains |
| WO2025255027A1 (en) * | 2024-06-03 | 2025-12-11 | Flagship Labs 114, Inc. | Lipid nanoparticles for topical delivery |
| WO2026047603A1 (en) | 2024-08-28 | 2026-03-05 | BioNTech SE | Sars-cov-2 immunogenic compositions |
| WO2026057625A1 (en) | 2024-09-11 | 2026-03-19 | BioNTech SE | Peptidoglycan hydrolases having a chap domain with engineered active site |
| WO2026057626A1 (en) | 2024-09-11 | 2026-03-19 | BioNTech SE | Peptidoglycan hydrolases having multiple enzymatically active domains |
| WO2026068864A1 (en) | 2024-09-30 | 2026-04-02 | BioNTech SE | Engineered ch1 and cl domains for the prevention of chain mispairing |
| CN121421963A (zh) * | 2026-01-04 | 2026-01-30 | 广州隽沐生物科技股份有限公司 | 一种用于难溶性活性经皮黏膜给药的装配材料及制备方法 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20100015218A1 (en) * | 2007-02-16 | 2010-01-21 | Vasant Jadhav | Compositions and methods for potentiated activity of biologically active molecules |
| JP6093710B2 (ja) * | 2011-11-18 | 2017-03-08 | 日油株式会社 | 細胞内動態を改善したカチオン性脂質 |
| HK1206644A1 (en) * | 2012-03-29 | 2016-01-15 | Shire Human Genetic Therapies, Inc. | Lipid-derived neutral nanoparticles |
| EP4286012A3 (en) * | 2015-09-17 | 2024-05-29 | ModernaTX, Inc. | Compounds and compositions for intracellular delivery of therapeutic agents |
| US11395798B2 (en) * | 2015-10-08 | 2022-07-26 | Nof Corporation | O/W type emulsion |
| WO2017189870A1 (en) * | 2016-04-27 | 2017-11-02 | Massachusetts Institute Of Technology | Stable nanoscale nucleic acid assemblies and methods thereof |
| US11583504B2 (en) * | 2016-11-08 | 2023-02-21 | Modernatx, Inc. | Stabilized formulations of lipid nanoparticles |
| AU2018330208B2 (en) * | 2017-09-08 | 2025-04-17 | Generation Bio Co. | Lipid nanoparticle formulations of non-viral, capsid-free DNA vectors |
| WO2019188867A1 (ja) * | 2018-03-27 | 2019-10-03 | 日油株式会社 | 細胞内動態を改善した新規カチオン性脂質 |
| JP7700101B2 (ja) * | 2019-09-06 | 2025-06-30 | ジェネレーション バイオ カンパニー | 閉端ｄｎａおよび切断可能脂質を含む脂質ナノ粒子組成物ならびにそれらの使用方法 |
| AU2020385378A1 (en) * | 2019-11-22 | 2022-04-07 | Generation Bio Co. | Ionizable lipids and nanoparticle compositions thereof |
| IL296763B2 (en) * | 2020-03-27 | 2026-04-01 | Generation Bio Co | New lipids and their nanoparticle compositions |
| US20230181764A1 (en) * | 2020-05-18 | 2023-06-15 | Generation Bio Co. | Novel lipids and nanoparticle compositions thereof |
-
2021
- 2021-07-16 MX MX2023000806A patent/MX2023000806A/es unknown
- 2021-07-16 JP JP2023502945A patent/JP2023534043A/ja active Pending
- 2021-07-16 IL IL299896A patent/IL299896A/en unknown
- 2021-07-16 CA CA3186033A patent/CA3186033A1/en active Pending
- 2021-07-16 WO PCT/US2021/042033 patent/WO2022016089A2/en not_active Ceased
- 2021-07-16 CN CN202180063144.XA patent/CN116437964A/zh active Pending
- 2021-07-16 KR KR1020237005643A patent/KR20230052895A/ko active Pending
- 2021-07-16 US US18/015,575 patent/US20230320993A1/en active Pending
- 2021-07-16 EP EP21842533.8A patent/EP4181948A4/en active Pending
- 2021-07-16 AU AU2021307952A patent/AU2021307952A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP4181948A2 (en) | 2023-05-24 |
| WO2022016089A2 (en) | 2022-01-20 |
| KR20230052895A (ko) | 2023-04-20 |
| CA3186033A1 (en) | 2022-01-20 |
| AU2021307952A1 (en) | 2023-03-02 |
| IL299896A (en) | 2023-03-01 |
| JP2023534043A (ja) | 2023-08-07 |
| WO2022016089A3 (en) | 2022-03-03 |
| CN116437964A (zh) | 2023-07-14 |
| US20230320993A1 (en) | 2023-10-12 |
| EP4181948A4 (en) | 2024-12-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2023000806A (es) | Métodos para encapsular polinucleótidos en tamaños reducidos de nanopartículas lipídicas y formulación novedosa de estos. | |
| CY1125154T1 (el) | Ενωσεις και συνθεσεις για ενδοκυτταρικη χορηγηση θεραπευτικων παραγοντων | |
| ZA202103233B (en) | Lipid nanoparticle formulations | |
| CR20200408A (es) | Nuevos péptidos y nuevas combinaciones de péptidos para el uso en la misma terapia contra el cáncer epitelial de ovario y otros tipos de cáncer (divisional 2018-0027). | |
| PE20200781A1 (es) | Proteinas de union a antigenos de maduracion de celulas b (bcma), de un solo dominio | |
| MX2019011215A (es) | Ácidos nucleicos que codifican proteínas asociadas a crispr y usos de los mismos. | |
| CR20180492A (es) | Células t transfectadas y receptores de células t de utilidad en inmunoterapias contra el cáncer | |
| CO2018012099A2 (es) | Composiciones y métodos para programar células terapéuticas utilizando nanoportadores de ácidos nucleicos dirigidos | |
| MX390848B (es) | Factor ix modificado, y composiciones, metodos y usos para la transferencia de genes a celulas, organos y tejidos. | |
| PE20230431A1 (es) | Anticuerpos de cadena pesada multiespecificos con regiones constantes de cadena pesada modificadas | |
| CR20170584A (es) | Neoantígenos compartidos | |
| EP4614148A3 (en) | Synergistic enhancement of the delivery of nucleic acids via blended formulations | |
| CR20170419A (es) | Nuevos péptidos y nueva combinación de péptidos para el uso en la inmunoterapia contra el cáncer de páncreas y otros tipos de cáncer. | |
| MX2023006203A (es) | Vacunas novedosas contra el virus de zika. | |
| WO2017156311A3 (en) | Combination vectors and methods for treating cancer | |
| AR081809A1 (es) | Composiciones farmaceuticas que comprenden un polipeptido que comprende al menos un motivo cxxc y antigenos heterologos y usos de las mismas | |
| MX2019011621A (es) | Inmunoterapia novedosa contra varios tumores, tales como cancer de pulmon, que incluye cancer de pulmon de celula no pequeña (nsclc). | |
| García-Quiroz et al. | The interaction of human papillomavirus infection and prostaglandin E2 signaling in carcinogenesis: a focus on cervical cancer therapeutics | |
| WO2023049636A3 (en) | Cancer therapy compositions and uses thereof | |
| EA201990711A1 (ru) | Новый ehv сайт инсерции orf70 | |
| MX2021005910A (es) | Formulacion de proteina de alta concentracion. | |
| EA201990689A1 (ru) | Бактериальные мини-клетки для доставки адъювантов на основе нуклеиновых кислот и способы их применения | |
| MX384635B (es) | Formulaciones de proteína estables que comprenden un exceso molar de sorbitol. | |
| AR069958A1 (es) | Metodo para producir una proteina heterologa de interes | |
| MX2022013632A (es) | Construcciones de union al antigeno dirigidas a her2 y sus usos. |